Corticosteroid-resistant GVHD is difficult to manage and is associated with high morbidity and mortality. Cyclophosphamide (Cy) is an established immunosuppressive and cytotoxic drug widely used as part of pretransplant conditioning regimens. In a retrospective study of 15 patients who had not responded to corticosteroids (nine with acute GVHD, three with GVHD after donor leukocyte infusion, and three progressive chronic GVHD), pulse Cy at a median dose of 1 g/m 2 was very effective in the treatment of skin (100% response), liver (70% response), and the oral cavity (100% response). Severe intestinal GVHD responded poorly. The toxicity profile was acceptable, with manageable, short-term myelosuppression in some patients. The risk of opportunistic infections, mixed chimerism, relapses, or post-transplant lymphoproliferative disease was not increased. Overall survival was 57%, with median and maximum follow-up of 9 and 37 months, respectively. The cost of the drug was negligible, especially when compared to monoclonal antibodies. Pulse Cy requires further investigation in corticosteroid-resistant GVHD. Bone Marrow Transplantation (2005) 35, 699-705.
suppression GVHD is common after non-T-cell-depleted allogeneic hematopoietic stem cell transplantation. [1] [2] [3] Corticosteroids comprise standard first-line treatment of GVHD and are variably effective. 4, 5 Corticosteroid-resistant GVHD is difficult to manage, and is associated with high morbidity and mortality. [6] [7] [8] Cyclophosphamide (Cy) has long been used as an immunosuppressive and cytotoxic drug, in the hematopoietic stem cell transplantation (HSCT) and nontransplant settings. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] There are reports describing the successful use of high-dose Cy (200 mg/kg), together with other immunosuppressive drugs, supported by autologous or pseudoautologous HSCT as therapy of severe GVHD. 12, 13 This high dose of Cy, however, led to the recurrence of a basic malignancy or total graft ablation.
We sought to explore pulse Cy in the treatment of GVHD based on the following: (1) the dismal prognosis of patients with steroid-refractory GVHD; (2) the published efficacy of Cy at the dose of 200 mg/kg for the treatment of GVHD; (3) the established efficiency of Cy for the treatment of many autoimmune disorders and for immunosuppression before allogeneic hematopoietic stem cell transplantation; and (4) the autoimmune nature of GVHD. Here, we report on the results of the treatment of steroidresistant GVHD with pulse Cy in 15 patients. This retrospective analysis has extended our experience previously reported in abstract form. 20, 21 Patients and methods
Transplantation, GVHD prophylaxis, and GVHD first-line therapy
The two preparative regimens most frequently used were busulfan þ Cy (myeloablative) and busulfan þ fludarabine þ antithymocyte globulin (ATG) (nonmyeloablative). Blood was the source of stem cells in all cases. GVHD prophylaxis consisted of cyclosporine and short-course methotrexate (myeloablative), or cyclosporine alone (nonmyeloablative). GVHD was diagnosed and staged according to standard criteria. 22 The recently described hepatitic variant of GVHD 23 is not included in this GVHD staging system, and was diagnosed on the basis of marked serum aminotransferase (ALT or AST) elevation (more than 10 times the upper normal limit) and exclusion of other potential causes. 23 Extensive tests were performed to achieve a precise diagnosis of GVHD. The first treatment in all patients was prednisone or methylprednisolone at a dose of 2 mg/kg/day or higher, together with cyclosporine. Steroid-refractory GVHD was defined as lack of response to steroids administered for at least 5 consecutive days.
Pulse Cy treatment and evaluation of response
For GVHD progressing on or unresponsive to initial treatment, Cy was administered at a dose of 1000 mg/m 2 as an i.v. infusion under vigorous hydration. In the cases where there was a fear of profound myelotoxicity or where the previous pulse was of limited effect, the Cy dose was empirically decreased or increased, respectively. In some cases, pulse Cy was administered even as an ambulatory treatment. Mesna and/or growth factors were not routinely used. When myelosuppression occurred, it was managed in the standard way (erythrocyte and platelet transfusion, antimicrobial agents, rarely G-CSF). Continuous administration of cyclosporine was not interrupted during Cy treatment, and steroids were slowly tapered.
Responses were assessed in each involved organ. Complete response (CR) signified the resolution of the manifestation of acute GVHD and partial response (PR) signified a decrease in organ stage by 1. Since there are no generally accepted staging criteria for the hepatitic variant of GVHD or for oral cavity involvement, we used a simple working classification system: hepatitic variant of liver GVHD: PR -decrease in the level of aminotransferases to values 42 Â upper normal limit and o50% of initial levels, CR -decrease in the level of aminotransferases to values p2 Â upper normal limit; oral mucosa involvement: PR -significant subjective and objective improvement, CR -complete resolution.
Statistical analysis
Standard descriptive statistics (median, maximum, minimum) were computed for all quantitative characteristics. Dependency on the presence or absence of gut involvement on survival was tested by univariate Cox proportional hazard regression and the Peto-Wilcoxon test, and the survival function of patients was estimated by the KaplanMeier method. Statistical analysis was performed either for the whole group of patients, or for the separate group of 12 patients with true aGVHD developing until the day þ 100 after the transplantation or donor lymphocyte infusion (DLI). ). The time intervals between two administered Cy pulses in patient nos. 2 and 4 were 17 and 27 days, respectively. Some patients had failed additional treatments before Cy pulse (mycophenolate mofetil, intra-arterial steroid administration 24, 25 ). Detailed data on individual patients are shown in Table 1 . The first nine patients (nos. 1-9) are patients with acute GVHD developing throughout day þ 100 after the transplantation. This group is followed by three patients (nos. [10] [11] [12] in whom GVHD developed after the DLI. The last three patients developed steroidrefractory GVHD beyond day þ 100 after the transplantation (nos. [13] [14] [15] . However, all these three patients also have had acute GVHD and their problems were in fact a continuation from acute GVHD.
Response to therapy
Response data are shown in Table 2 . Skin and oral involvement responded most frequently -in all cases. Treatment of liver involvement was also successful -70% of patients responded to Cy pulse. The therapeutic response was often seen as early as a few days after Cy administration. Intestinal GVHD resulted in the lowest response rate. In fact there was no clear long-lasting treatment response after the administration of Cy alone. On the other hand, the clinical status in two patients improved (PR), stabilized, and later normalized when other therapeutic measures were performed -addition of mycophenolate mofetil or intraarterial steroid administration. It is noteworthy that in both patients in whom there was no clear response to hepatic GVHD, there was also intestinal GVHD, which was unresponsive to the therapy. All patients with refractory intestinal GVHD died.
Myelotoxicity of pulse Cy
The myelotoxicity was usually brief, mild, and easily manageable. A great variation in the myelosuppressive effect of pulse Cy exists. Median WBC and platelet counts before Cy pulse were 5.93 Â 10 9 /l (range 1.18-16.3) and 97 Â 10 9 /l (range ), respectively; median lowest WBC and platelet counts after Cy pulse were 0.76 (range 0.05-16.3) and 73 (range 7-223), respectively. Leukopenia WHO grade 1, 2, 3, and 4 developed after one, one, one, and nine Cy pulses, respectively, and thrombocytopenia WHO grade 1, 2, 3, and 4 developed after three, three, three, and three Cy pulses. WBC and platelet nadirs occurred on the same day, 10 days (median 6-15 days) after the Cy pulse. When myelosuppression developed, it was usually short-lived (1-4 days). However, in case nos. 1, 5, and 15, myelosuppression lasted 9, 7, and 18 days, respectively. The variations of absolute neutrophil counts after Cy pulse for all 17 administrations are shown in Figure 1 .
Other toxicities, influence of chimerism and disease status, and overall survival Toxicity of pulse Cy treatment was low. Except for complications due to neutropenia, there were few other complications. However, it is not always possible to directly connect complication to cause in such a complex clinical situation as steroid-refractory GVHD. There were nine episodes with at least 1 day of WBC count below 1 Â 10 9 /l, and five of them were complicated by various infections: febrile neutropenia (three), peripheral vein catheter infection (one), and pneumonia responding to antibiotics (one). Pneumonia developed in a patient whose GVHD was not responding to any treatment and who eventually died. Other infectious complications included CMV PCR positivity in blood (three) and BK virus positivity in urine Table 1 Basic clinical and laboratory data of the steroid-resistant GVHD patients, response to pulse Cy therapy, and its complications Table 1 . Six patients died. In five of them, the direct cause of death was therapy-refractory intestinal GVHD and one patient died from recurrent AML. Overall survival of all 15 patients is 57% with median and maximal follow-up of 9 and 37 months, respectively. When analyzing the whole group of patients, survival significantly depended on the presence or absence of gut involvement (Peto-Wilcoxon test, P ¼ 0.015; univariate Cox proportional hazard regression, P ¼ 0.05). For the subgroup of 12 patients with true acute GVHD, this dependence was of borderline significance due to the small number of cases.
Discussion
Evaluation of salvage therapy for steroid-resistant GVHD is difficult. The dose of steroids indicating resistance varied greatly between 1 and 40 mg/kg/day. 4 The length of the first-line treatment before it is classified as unsuccessful also varies widely: between 3 and 14 days. 8, [26] [27] [28] As can be seen from Table 1 , our patients also displayed a wide spectrum of GVHD manifestations and the time interval between the initial treatment and the start of Cy pulse (secondary treatment) varied; however, it was long enough to estimate the response to first-line therapy and to properly classify steroid refractoriness.
There is no simple, effective, or nontoxic therapy of corticosteroid-resistant acute GVHD. Options explored have been ATG, [29] [30] [31] [32] [33] monoclonal antibodies, 28,34-37 mycophenolate mofetil, 38 sirolimus (rapamycin), 39 pentostatin, 40 denileukin diftitox, 26 and other therapeutic procedures. While such comparisons are always difficult, it appears that pulse Cy shows results that are comparable to other second-line drugs. Currently, nine out of 15 patients are alive and the longest follow-up is now 37 months.
There were striking differences in response rates according to the involved organs. The worst response to Cy pulse was seen in patients with intestinal GVHD. In our group of patients, five out of seven with intestinal involvement died. These were the only patients who died directly from GVHD (patient nos. 3, 4, 6, 7, and 9 in Table 1 ). They probably had a very severe form of GVHD because they did not respond to further therapies, including monoclonal antibodies and local intra-arterial steroid administration. However, also in patients who survived their intestinal GVHD, no clear CR to Cy pulse has been seen. Moreover, in two patients, there was a good response followed by early relapses of their GVHD symptoms (patient nos. 4 and 5). Therefore, pulse Cy treatment does not seem to be very effective in treating severe intestinal acute GVHD. MacMillan et al 41 analyzed the response to steroids as the primary therapy of acute GVHD and also found that lower gastrointestinal GVHD had a lower response rate. Several other studies dealing with patients with steroid-refractory acute GVHD described quite low response rates when the gut was involved: treatment with ATG (CR þ PR; 33 and 32%) 30, 32 or daclizumab (CR; 37%). 34 On the other hand, however, some studies described a quite good response rate in the gut involvement: treatment with infliximab (CR þ PR; 75%) 35 or denileukin diftitox (CR þ PR; 75%). 26 There is no clear explanation for these findings. In contrast to our data, several studies also described quite low efficiency , and achievement of CR after intra-arterial therapy. b In both cases, there was liver GVHD together with nonresponsive intestinal GVHD c CR after intra-arterial therapy (one case) and the addition of mycophenolate mofetil (one case) d All these patients died; these were the only patients from the whole group who died from GVHD e Involvement of oral cavity was included in this analysis. In fact, it developed in all four patients after day +100 after transplantation. In two cases, oral mucositis was a part of GVHD manifestation upon DLI, and in the other two cases, there was a link of this involvement with true acute GVHD. Pulse cyclophosphamide and GVHD J Mayer et al for different drugs in the treatment of hepatic GVHD. 23, 26, 29, 30, 32, 34, 35 We would like to emphasize, however, that different subgroups belonged to our group of hepatic GVHD (true acute GVHD, post-DLI GVHD, and chronic GVHD after acute GVHD). Despite this, we think that the efficiency of pulse Cy in liver GVHD deserves further attention.
We looked very thoroughly at the toxicity profile of this novel treatment. As expected, Cy caused myelosuppression. It is important to note that not all patients experienced this side effect and leukopenia is more frequent than thrombocytopenia. When myelosuppression occurred, it was usually brief. Since it is known that hematopoietic stem cell transplantation causes a long-term decrease in marrow progenitor cell counts, 42, 43 one could expect a more pronounced myelosuppression. Furthermore, a trial with a high dose of Cy (200 mg/kg total dose) in aplastic anemia had to be stopped prematurely due to excess morbidity and mortality. 19 However, it is also known that a high dose of Cy up to 7000 mg/m 2 does not cause irreversible marrow damage. These dosages were used with or without growth factors for PBSC mobilization. 44 Cy has also been used at the dosage of 50 mg/kg on day þ 3 after the nonmyeloablative hematopoietic stem cell transplantation, without any detrimental effect on engraftment. 11 The unique pharmacology of high-dose Cy is responsible for inducing maximal immunosuppression without myeloablation. Hematopoietic stem cells express high levels of aldehyde dehydrogenase, an enzyme responsible for cellular resistance to Cy, whereas B-lymphocytes, T-lymphocytes, and NK cells express low levels of the enzyme and are extremely sensitive to the cytotoxic properties of Cy. 45 Myelosuppression caused by pulse Cy for the treatment of GVHD does not seem to cause serious morbidity and its management does not differ from other cytotoxic drug-induced brief myelosuppression. In one patient, autopsy found pulmonary aspergillosis (no. 3; Table 1 ). It should be noted, however, that this patient was retransplanted shortly after the first transplant because of leukemia relapse, and also received a high-dose methylprednisolone and infliximab as GVHD therapy. In one study, infliximab administration has been shown to be associated with significantly increased risk of invasive fungal infections. 46 The frequency of other opportunistic infections also does not seem to have increased in our study and these infections did not cause mortality. We recommend a careful CMV and BK virus monitoring. Importantly, pulse Cy also does not seem to increase the risk of a relapse in the basic malignant disease. Only one patient died from a relapse and it should be noted that it was the second relapse of his AML. GVHD, which was treated by pulse Cy, developed after DLI treatment of the first relapse. In other patients, Cy administration does not influence either the chimerism status or minimal residual disease. This safety profile might favor Cy usage instead of other drugs with more pronounced immunosuppressive effects. Last but not least, Cy treatment is very cheap.
In conclusion, we can state that pulse Cy is an effective treatment of steroid-refractory GVHD of the skin and liver and produces long-term control over this post transplant complication. Its ability to control intestinal GVHD is much lower, however. Pulse Cy, except for myelosuppression of short duration in some patients, exerts a remarkably good toxicity profile and does not seem to increase the risk of opportunistic infections, relapses, or post transplant lymphoproliferative disease. The cost of the drug is negligible. In future trials, this drug could also be tested in combination with other drugs with different mechanisms of action.
